Stress pathway antibodies are read as a change rather than as a level, and that is what makes them easy to misuse. An autophagy marker rises when the pathway runs and again when it is blocked, a mitotic kinase's abundance follows the cell cycle rather than a treatment, and an oxidative damage adduct is measured as a modification on other proteins entirely. Each one needs a control that says which of those is happening.
A pink1 antibody and an atg16l1 antibody on the pathway machinery
Mitophagy and autophagy machinery components are low abundance and, in the kinase's case, unstable until mitochondrial damage stabilises it, so a blot of untreated cells reading nothing is the expected result rather than a failed antibody. The positive control is a depolarising treatment at a documented time point, and the interpretation needs mitochondrial fractionation to separate recruitment from expression. The complex subunit is better read as puncta than as a band, which makes the imaging clone and its fixation the relevant specification.
A survivin antibody and a plk1 antibody through the cell cycle
Both proteins peak in mitosis and are degraded on exit, so abundance in an unsynchronised culture reports the proportion of mitotic cells, and a treatment that arrests cells raises the signal without changing expression. The honest experiment is either a synchronised series with a cell cycle marker beside it, or flow cytometry that reads the protein per cell against DNA content. Phospho-specific clones against activation sites are the readout for kinase activity, and they need a mitotic positive control lysate rather than an asynchronous one.
A calreticulin antibody and a 4 hne antibody on stress and oxidation
The chaperone is an abundant endoplasmic reticulum protein used both as a compartment marker and, when it reaches the surface, as an immunogenic cell death signal, and those two readings need different methods: a blot or a section for the first, live cell surface staining without permeabilisation for the second. The lipid peroxidation adduct is not a protein at all: the antibody detects a modification carried on many proteins, so the result is a smear of modified species and the control is a sample treated to generate or scavenge the adduct.
A p21 antibody and a gspt1 antibody on arrest and degradation
The cyclin dependent kinase inhibitor is induced by damage and degraded quickly, so a lysate prepared slowly under-reports it and a proteasome inhibited sample over-reports it; both belong in the experiment once. The translation termination factor is interesting mainly as a degradation target of molecular glue compounds, which means the readout is loss of the band on treatment, with a time course and a control protein that should not move. For both, the quantitative comparison is against total protein rather than against an abundant housekeeping band.
Flux against abundance, the mistake this class invites
An autophagy marker's abundance rises when degradation runs and also when the lysosome is blocked, so a single blot cannot tell induction from blockade. The standard answer is a flux experiment: the same treatment with and without a lysosomal inhibitor, read as the difference between the pairs rather than as either lane. The same logic covers proteasome substrates and short-lived regulators generally, which is why an inhibitor arm is not an extra control in this class but part of the measurement.
What to ask for when a treatment is the control
Because every reagent here is judged on a change, the datasheet's useful evidence is a treated against untreated pair in the application you will run, with the agent, the concentration and the time stated. Ask for it, and where a vendor shows only an overexpressing lysate, plan the positive control yourself before the experiment rather than after a blank membrane. Record the treatment with the clone in the method, since half the disagreements in this literature are about how the positive control was generated.
Questions people ask about lc3 antibody
Why does an autophagy marker rise in both directions?
Because it is degraded by the pathway it marks. Run the treatment with and without a lysosomal inhibitor and read the difference between the pairs.
Is a mitotic kinase's abundance a treatment effect?
Usually not. It follows the proportion of mitotic cells, so synchronise or read per cell against DNA content.
What does a 4-HNE antibody detect?
A lipid peroxidation adduct carried on many proteins, so the result is a pattern of modified species rather than one band.